{"id":"thymosin-alpha-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Thymosin Alpha 1 is a naturally occurring peptide derived from the thymus gland that acts as an immunomodulator. It enhances T-cell development and maturation, increases natural killer cell activity, and promotes the production of cytokines that support immune responses. The drug is used to restore or enhance immune function in patients with compromised immunity or chronic infections.","oneSentence":"Thymosin Alpha 1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic differentiation and activation of immune cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:45.698Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"},{"name":"Immunodeficiency states"},{"name":"Recurrent infections"}]},"trialDetails":[{"nctId":"NCT07277439","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-16","conditions":"Gastric Cancer","enrollment":48},{"nctId":"NCT06461910","phase":"PHASE2","title":"Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zekuan Xu","startDate":"2024-06-14","conditions":"Gastric Cancer, Esophagogastric Junction Adenocarcinoma","enrollment":30},{"nctId":"NCT07382375","phase":"NA","title":"AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Medical University","startDate":"2027-12-31","conditions":"Aortic Aneurysm and Dissection","enrollment":300},{"nctId":"NCT06552598","phase":"PHASE1","title":"The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-04-01","conditions":"Cervical Cancer, Gynecologic Malignancies, Endometrial Cancer","enrollment":97},{"nctId":"NCT07103395","phase":"PHASE2","title":"A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Lung Cancer (NSCLC)","enrollment":56},{"nctId":"NCT06966687","phase":"NA","title":"Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)","status":"ENROLLING_BY_INVITATION","sponsor":"Nanjing Medical University","startDate":"2025-04-01","conditions":"Aortic Dissection, Aortic Dissection Aneurysm","enrollment":200},{"nctId":"NCT06139419","phase":"PHASE2","title":"The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-25","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT04428008","phase":"PHASE2","title":"Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients","status":"COMPLETED","sponsor":"William B. Ershler, MD","startDate":"2021-01-12","conditions":"COVID-19","enrollment":262},{"nctId":"NCT07103408","phase":"PHASE2","title":"A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-10-01","conditions":"Small-Cell Lung Cancer (SCLC)","enrollment":56},{"nctId":"NCT06821100","phase":"PHASE1","title":"Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-02","conditions":"Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination","enrollment":75},{"nctId":"NCT06056804","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-01-03","conditions":"Locally Advanced Rectal Cancer","enrollment":20},{"nctId":"NCT06829355","phase":"PHASE2","title":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-02-11","conditions":"MCRC","enrollment":52},{"nctId":"NCT05339529","phase":"NA","title":"Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)","status":"RECRUITING","sponsor":"Nanjing Medical University","startDate":"2022-07-01","conditions":"Acute Aortic Syndrome, Aortic Dissection Type a","enrollment":330},{"nctId":"NCT06607926","phase":"NA","title":"Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-15","conditions":"Resectable Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT06584006","phase":"PHASE2","title":"Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-09-01","conditions":"Hematological Malignancy, Lymphocytopenia","enrollment":50},{"nctId":"NCT06598839","phase":"NA","title":"Immuno-effect of Tα1 for Stage I NSCLC","status":"RECRUITING","sponsor":"Yousheng Mao","startDate":"2024-06-30","conditions":"Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06573398","phase":"PHASE2","title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Carcinoma, Pancreatic Ductal","enrollment":20},{"nctId":"NCT06401447","phase":"NA","title":"TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06178146","phase":"PHASE4","title":"Thymosin Alpha-1 for irAE Secondary to ICIs","status":"UNKNOWN","sponsor":"Jun Wang","startDate":"2023-09-01","conditions":"IrAE","enrollment":40},{"nctId":"NCT02535988","phase":"PHASE2","title":"Abscopal Effect for Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2015-09","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, Thymalfasin","enrollment":""},{"nctId":"NCT06024356","phase":"","title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2023-09-20","conditions":"Colorectal Neoplasms","enrollment":26},{"nctId":"NCT04963712","phase":"EARLY_PHASE1","title":"Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder","status":"COMPLETED","sponsor":"Shanghai Public Health Clinical Center","startDate":"2021-09-01","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT02867267","phase":"PHASE3","title":"The Efficacy and Safety of Ta1 for Sepsis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-09-06","conditions":"Sepsis","enrollment":1106},{"nctId":"NCT05790447","phase":"PHASE2","title":"Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-04-01","conditions":"Advanced Solid Tumor, Refractory Tumor","enrollment":60},{"nctId":"NCT04487444","phase":"PHASE2","title":"Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection","status":"TERMINATED","sponsor":"Rhode Island Hospital","startDate":"2020-09-10","conditions":"Covid19","enrollment":56},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT05487469","phase":"NA","title":"Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2022-07-01","conditions":"Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy","enrollment":200},{"nctId":"NCT03659578","phase":"PHASE2","title":"Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-08-09","conditions":"Non-small Cell Lung Cancer","enrollment":69},{"nctId":"NCT05086614","phase":"PHASE3","title":"Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-04-01","conditions":"Stage II Colorectal Cancer, Stage III Colorectal Cancer","enrollment":2500},{"nctId":"NCT03082885","phase":"NA","title":"The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-04-10","conditions":"Liver Failure","enrollment":120},{"nctId":"NCT04901104","phase":"","title":"Long-term Prognosis of Patients With Sepsis After Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-07-01","conditions":"Long-term Effects of Thymosin Alpha 1 Treatment","enrollment":900},{"nctId":"NCT02473406","phase":"PHASE4","title":"Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis","status":"COMPLETED","sponsor":"Weiqin Li","startDate":"2018-03-27","conditions":"Pancreatitis, Acute Necrotizing","enrollment":508},{"nctId":"NCT04524169","phase":"PHASE4","title":"Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-11-01","conditions":"Osteoporotic Pain","enrollment":100},{"nctId":"NCT04320238","phase":"PHASE3","title":"Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-01-21","conditions":"2019 Novel Coronavirus Infection","enrollment":2944},{"nctId":"NCT02883595","phase":"PHASE4","title":"Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-03-31","conditions":"Sepsis","enrollment":20},{"nctId":"NCT02542930","phase":"PHASE2","title":"Abscopal Effect for Metastatic Non-small Cell Lung Cancer.","status":"WITHDRAWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2016-01","conditions":"Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Radiotherapy","enrollment":""},{"nctId":"NCT02542137","phase":"PHASE2","title":"Abscopal Effect for Metastatic Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2015-09","conditions":"Small Cell Lung Cancer, Radiotherapy, Thymalfasin","enrollment":""},{"nctId":"NCT01943617","phase":"PHASE4","title":"Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2013-06","conditions":"Liver Cirrhosis","enrollment":606},{"nctId":"NCT01938820","phase":"PHASE4","title":"Optimized Treatment and Regression of HBV-induced Early Cirrhosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2013-06","conditions":"Liver Cirrhosis","enrollment":82},{"nctId":"NCT03448744","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients","status":"UNKNOWN","sponsor":"Wen-hong Zhang","startDate":"2017-10-25","conditions":"Chronic Hepatitis b","enrollment":240},{"nctId":"NCT02545751","phase":"PHASE2","title":"SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer","status":"UNKNOWN","sponsor":"Hangzhou Cancer Hospital","startDate":"2016-01","conditions":"Esophageal Cancer, Metastatic Esophageal Cancer, Stereotactic Body Radiation Therapy","enrollment":29},{"nctId":"NCT02976740","phase":"PHASE2","title":"SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2016-11","conditions":"Lung Cancer Metastatic","enrollment":48},{"nctId":"NCT02787447","phase":"PHASE2","title":"Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2016-05","conditions":"Lung Adenocarcinoma","enrollment":46},{"nctId":"NCT02906150","phase":"PHASE2","title":"Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type","status":"UNKNOWN","sponsor":"SciClone Pharmaceuticals","startDate":"2016-09","conditions":"Non-Small Cell Lung Cancer","enrollment":140},{"nctId":"NCT02906163","phase":"PHASE1, PHASE2","title":"First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy","status":"UNKNOWN","sponsor":"SciClone Pharmaceuticals","startDate":"2016-10","conditions":"EGFR Mutation Positive Non Small Cell Lung Cancer","enrollment":188},{"nctId":"NCT02646189","phase":"PHASE1, PHASE2","title":"Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2011-08","conditions":"Hepatitis B, Chronic","enrollment":12},{"nctId":"NCT02366208","phase":"PHASE2","title":"Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2011-05","conditions":"Hepatitis B, Chronic","enrollment":116},{"nctId":"NCT02366247","phase":"PHASE3","title":"Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":"Hepatitis B, Chronic","enrollment":463},{"nctId":"NCT02281266","phase":"PHASE4","title":"Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection","status":"UNKNOWN","sponsor":"Jia Fan","startDate":"2015-01","conditions":"Curable Hepatitis B Virus-Related Hepatocellular Carcinoma","enrollment":360},{"nctId":"NCT00935558","phase":"PHASE2","title":"Dendritic Cell Based Therapy for Breast Cancer Patients","status":"WITHDRAWN","sponsor":"Inge Marie Svane","startDate":"2009-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01031966","phase":"PHASE2","title":"A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2009-11","conditions":"END STAGE RENAL DISEASE","enrollment":120},{"nctId":"NCT00197860","phase":"PHASE1, PHASE2","title":"Dendritic Cell Based Therapy of Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2004-09","conditions":"Advanced Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT00291616","phase":"PHASE4","title":"Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2005-12","conditions":"Chronic Hepatitis B","enrollment":52},{"nctId":"NCT00711620","phase":"NA","title":"Efficacy of Thymosin alpha1 for Severe Sepsis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2008-05","conditions":"Severe Sepsis","enrollment":366},{"nctId":"NCT01178996","phase":"PHASE3","title":"Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":552},{"nctId":"NCT00911443","phase":"PHASE2","title":"Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2002-07","conditions":"Malignant Melanoma","enrollment":488},{"nctId":"NCT00001036","phase":"PHASE1","title":"The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00040027","phase":"PHASE3","title":"Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin","status":"COMPLETED","sponsor":"SciClone Pharmaceuticals","startDate":"2002-04","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":500},{"nctId":"NCT00039962","phase":"PHASE3","title":"Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin","status":"COMPLETED","sponsor":"SciClone Pharmaceuticals","startDate":"2002-05","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":500},{"nctId":"NCT00082082","phase":"PHASE2","title":"A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"SciClone Pharmaceuticals","startDate":"","conditions":"Carcinoma, Hepatocellular","enrollment":""},{"nctId":"NCT00580450","phase":"PHASE1, PHASE2","title":"Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies","status":"UNKNOWN","sponsor":"University Of Perugia","startDate":"2007-12","conditions":"Hematological Malignancies","enrollment":9}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"OFF LABEL USE"},{"count":3,"reaction":"FATIGUE"},{"count":2,"reaction":"ABORTION SPONTANEOUS"},{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"INTERSTITIAL LUNG DISEASE"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PAIN"},{"count":2,"reaction":"PERIPHERAL ISCHAEMIA"},{"count":2,"reaction":"PNEUMONIA"},{"count":2,"reaction":"PREGNANCY"}],"_approvalHistory":[],"publicationCount":575,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["thymalfasin","thymosin α","Zadaxin","Thymosin Group"],"phase":"marketed","status":"active","brandName":"Thymosin Alpha 1","genericName":"Thymosin Alpha 1","companyName":"Xuanwu Hospital, Beijing","companyId":"xuanwu-hospital-beijing","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thymosin Alpha 1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic differentiation and activation of immune cells. Used for Chronic hepatitis B, Chronic hepatitis C, Immunodeficiency states.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}